Enhanced Innate and Acquired Immune Responses in Systemic Sclerosis Primary Peripheral Blood Mononuclear Cells (PBMCs)

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Oct 14

PMID 37833885

Authors

Iulia Szabo

Medeea Badii

Ildiko O Gaal

Robert Szabo

Radu A Popp

Leo A B Joosten

Tania O Crisan

Simona Rednic

Affiliations

Soon will be listed here.

Abstract

Chronic immune activation in systemic sclerosis is supported by the production of a plethora of cytokines with proven regulatory activities of the immune responses. This study aimed to explore PBMCs' cytokine profiles in SSc patients versus controls, as well as to investigate the balance between pro- and anti-inflammatory cytokines in association with disease duration. PBMCs were isolated from 18 SSc patients and 17 controls and further subjected to in vitro stimulation with lipopolysaccharide and heat-killed . Cytokine production was measured after 24 h and 7 days, respectively, using ELISA kits for interleukin (IL)-1β, IL-1 receptor antagonist (IL-1Ra), IL-6, tumor necrosis factor (TNF), IL-10, IL-17, and interferon-gamma (IFN-gamma). IL-1 β, IL-6, and TNF levels were increased in SSc patients compared with healthy volunteers irrespective of the stimulus used. IL-1Ra and Il-17 concentrations were not statistically different between groups, even though a trend toward higher levels in patients compared with their matched controls was also observed. Most cytokines demonstrated a stable course with disease progression, except for IL-10 levels, which declined over time. In conclusion, the results of this pilot study reveal that in patients with SSc a persistently enhanced immune response is established and maintained regardless of stimulus or disease duration.

References

Moreno-Moral A, Bagnati M, Koturan S, Ko J, Fonseca C, Harmston N . Changes in macrophage transcriptome associate with systemic sclerosis and mediate contribution to disease risk. Ann Rheum Dis. 2018; 77(4):596-601. PMC: 5890626. DOI: 10.1136/annrheumdis-2017-212454. View

Kantor T, Friberg D, Medsger Jr T, Buckingham R, Whiteside T . Cytokine production and serum levels in systemic sclerosis. Clin Immunol Immunopathol. 1992; 65(3):278-85. DOI: 10.1016/0090-1229(92)90158-k. View

Arts R, Carvalho A, La Rocca C, Palma C, Rodrigues F, Silvestre R . Immunometabolic Pathways in BCG-Induced Trained Immunity. Cell Rep. 2016; 17(10):2562-2571. PMC: 5177620. DOI: 10.1016/j.celrep.2016.11.011. View

Gourh P, Arnett F, Assassi S, Tan F, Huang M, Diekman L . Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther. 2009; 11(5):R147. PMC: 2787259. DOI: 10.1186/ar2821. View

Mora V, Loaiza R, Soto J, Bohmwald K, Kalergis A . Involvement of trained immunity during autoimmune responses. J Autoimmun. 2022; 137:102956. DOI: 10.1016/j.jaut.2022.102956. View

Kamada R, Yang W, Zhang Y, Patel M, Yang Y, Ouda R . Interferon stimulation creates chromatin marks and establishes transcriptional memory. Proc Natl Acad Sci U S A. 2018; 115(39):E9162-E9171. PMC: 6166839. DOI: 10.1073/pnas.1720930115. View

Dantas A, de Almeida A, Sampaio M, Cordeiro M, Oliveira P, de Ataide Mariz H . Different profile of cytokine production in patients with systemic sclerosis and association with clinical manifestations. Immunol Lett. 2018; 198:12-16. DOI: 10.1016/j.imlet.2018.03.011. View

Liu C, Chu D, Kalantar-Zadeh K, George J, Young H, Liu G . Cytokines: From Clinical Significance to Quantification. Adv Sci (Weinh). 2021; 8(15):e2004433. PMC: 8336501. DOI: 10.1002/advs.202004433. View

Brown M, Postlethwaite A, Myers L, Hasty K . Supernatants from culture of type I collagen-stimulated PBMC from patients with cutaneous systemic sclerosis versus localized scleroderma demonstrate suppression of MMP-1 by fibroblasts. Clin Rheumatol. 2012; 31(6):973-81. PMC: 3362697. DOI: 10.1007/s10067-012-1962-z. View

10.

Sato S, Hasegawa M, Takehara K . Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci. 2001; 27(2):140-6. DOI: 10.1016/s0923-1811(01)00128-1. View

11.

Li H, Zhang X, Yu L, Shang J, Fan J, Feng X . Comparing clinical characteristics of systemic sclerosis with or without interstitial lung disease: A cross-sectional study from a single center of the Chinese Rheumatism Data Center. Front Med (Lausanne). 2022; 9:1061738. PMC: 9763297. DOI: 10.3389/fmed.2022.1061738. View

12.

Lakos G, Melichian D, Wu M, Varga J . Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet. Pathobiology. 2007; 73(5):224-37. DOI: 10.1159/000098208. View

13.

Xing X, Li A, Tan H, Zhou Y . IFN-γ IL-17 Th17 cells regulate fibrosis through secreting IL-21 in systemic scleroderma. J Cell Mol Med. 2020; 24(23):13600-13608. PMC: 7753990. DOI: 10.1111/jcmm.15266. View

14.

Zhu L, Fu X, Chen X, Han X, Dong P . M2 macrophages induce EMT through the TGF-β/Smad2 signaling pathway. Cell Biol Int. 2017; 41(9):960-968. DOI: 10.1002/cbin.10788. View

15.

Bhandari R, Ball M, Martyanov V, Popovich D, Schaafsma E, Han S . Profibrotic Activation of Human Macrophages in Systemic Sclerosis. Arthritis Rheumatol. 2020; 72(7):1160-1169. PMC: 7329566. DOI: 10.1002/art.41243. View

16.

Gur C, Wang S, Sheban F, Zada M, Li B, Kharouf F . LGR5 expressing skin fibroblasts define a major cellular hub perturbed in scleroderma. Cell. 2022; 185(8):1373-1388.e20. PMC: 7612792. DOI: 10.1016/j.cell.2022.03.011. View

17.

de Almeida A, Dantas A, de Oliveira Goncalves M, Chene C, Jeljeli M, Chouzenoux S . PPARγ partial agonist LPSF/GQ-16 prevents dermal and pulmonary fibrosis in HOCl-induced systemic sclerosis (SSc) and modulates cytokine production in PBMC of SSc patients. Inflammopharmacology. 2023; 32(1):433-446. DOI: 10.1007/s10787-023-01296-9. View

18.

Badii M, Gaal O, Popp R, Crisan T, Joosten L . Trained immunity and inflammation in rheumatic diseases. Joint Bone Spine. 2022; 89(4):105364. DOI: 10.1016/j.jbspin.2022.105364. View

19.

Umehara H, Kumagai S, Murakami M, Suginoshita T, Tanaka K, Hashida S . Enhanced production of interleukin-1 and tumor necrosis factor alpha by cultured peripheral blood monocytes from patients with scleroderma. Arthritis Rheum. 1990; 33(6):893-7. DOI: 10.1002/art.1780330619. View

20.

Duan H, Fleming J, Pritchard D, Amon L, Xue J, Arnett H . Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum. 2008; 58(5):1465-74. DOI: 10.1002/art.23451. View